FOR IMMEDIATE RELEASE

Contact:
Paul Byerley
Chief Executive Officer
+1 320.259.4321
pbyerley@artossinc.com

Artoss, Inc. Announces Record 2021 Revenue for NanoBone® Bone Graft Substitute

Significant growth highlights significant clinical quality

St. Cloud, MN, January 9, 2022 / -- Artoss, Inc. (St. Cloud, MN), a medical device company pioneering the use of advanced bone graft substitutes to treat multiple orthopaedic indications, announced record NanoBone Bone Graft Substitute products revenue for FY 2021, with over a 14% increase in revenue over 2020 and a 5% revenue increase versus the previous record set in 2019.

The 2021 annual revenue reinforces NanoBone's consistent and cost-effective outcomes in bone grafting in multiple orthopaedic indications, such as, spine surgery, orthopaedic trauma, and sports surgery. NanoBone achieves these outcomes with no preparation required, excellent handling for surgeons, creation of an osteogenic matrix within 14 days, and clinical and radiographic healing in as little as 8 weeks.

Paul Byerley, Chief Executive Officer of Artoss, Inc., the exclusive North American distributors for NanoBone®, commented, "This new record for revenue in 2021 was delivered despite continued challenges due to the Covid-19 pandemic. Our sales and marketing management team and independent distributors each contributed to this significant accomplishment for 2021 and their focused efforts allowed us to achieve this milestone during a global pandemic. It is noteworthy to see new orthopaedic surgeon customers and hospitals accept the clinical and cost efficacy of NanoBone as a standalone bone graft substitute."

Mr. Byerley added that the Company has succeeded through, "deliberate focus on our clinical and cost effectiveness through post-market Clinical Registries established in 2019 and 2020, some of which concluded in 2021 and are undergoing peer-review."

The continued growth in NanoBone procedures further secures its market position as a leader in the bone repair space. There is growing acceptance by orthopaedic surgeons that not all bone graft substitutes are the same, given the rapid osteogenic matrix formation of NanoBone within 14 days and evidence of clinical and radiographic healing within as little as 8 weeks.

###

About NanoBone

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical need and one where NanoBone may provide an effective option.

NanoBone is a commercially available product in the U.S. intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone® SBX Putty resorbs and is replaced with bone during the healing process.

###

About Artoss, Inc.

Artoss, Inc. (St. Cloud, MN) is a medical device company that is a leading distributor of bioidentical bone graft substitutes to treat multiple orthopaedic indications and is dedicated to the development of tools and products for effectively treating a variety of orthopaedic conditions requiring surgical intervention. The company markets NanoBone Bone Graft Substitute, which is gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.